EX-99.1 2 mnkex99107212022-gxproduct.htm EX-99.1

Exhibit 99.1

MALLINCKRODT PLC
SELECT PRODUCT LINE NET SALES
Three Months Ended April 1, 2022
(unaudited, in millions)
Specialty Brands
Acthar Gel			$	127.7
INOmax			99.0
Ofirmev			2.6
Therakos			59.9
Amitiza			47.7
Other			2.5
Specialty Brands Total			339.4
Specialty Generics
Opioids			50.0
ADHD			10.8
Addiction treatment			15.9
Other			2.8
Generics Subtotal			79.5
Controlled substances			20.4
APAP			46.3
Other			5.3
API Subtotal			72.0
Specialty Generics Total			151.5
Net sales			$	490.9

1

---

MALLINCKRODT PLC
SELECT PRODUCT LINE NET SALES
(unaudited, in millions)
			Three Months Ended																								Fiscal Year Ended
			March 26, 2021						June 25, 2021						September 24, 2021						December 31, 2021						December 31, 2021
Specialty Brands
Acthar Gel			$	129.0					$	151.5					$	143.4					$	169.7					$	593.6
INOmax			134.0						105.9						98.4						110.2						448.5
Ofirmev			12.8						6.5						4.7						4.9						28.9
Therakos			66.8						68.5						62.5						68.7						266.5
Amitiza			61.4						44.8						49.6						41.1						196.9
Other			4.4						4.3						1.1						2.8						12.6
Specialty Brands Total			408.4						381.5						359.7						397.4						1,547.0
Specialty Generics
Opioids			54.7						53.8						46.5						58.2						213.2
ADHD			8.3						7.8						8.7						12.6						37.4
Addiction treatment			16.4						16.0						15.3						20.6						68.3
Other			1.9						3.6						2.9						3.6						12.0
Generics Subtotal			81.3						81.2						73.4						95.0						330.9
Controlled substances			17.4						25.6						19.4						31.0						93.4
APAP			45.5						51.7						49.6						69.1						215.9
Other			5.4						6.4						5.1						4.7						21.6
API Subtotal			68.3						83.7						74.1						104.8						330.9
Specialty Generics Total			149.6						164.9						147.5						199.8						661.8
Net sales			$	558.0					$	546.4					$	507.2					$	597.2					$	2,208.8

2

---

MALLINCKRODT PLC
SELECT PRODUCT LINE NET SALES
Fiscal Year Ended December 25, 2020
(unaudited, in millions)
Specialty Brands
Acthar Gel			$	767.9
INOmax			574.1
Ofirmev			276.5
Therakos			238.6
Amitiza			188.8
Other			13.7
Specialty Brands Total			2,059.6
Specialty Generics
Opioids			233.9
ADHD			48.3
Addiction treatment			68.9
Other			7.3
Generics Subtotal			358.4
Controlled substances			98.3
APAP			213.0
Other			20.1
API Subtotal			331.4
Specialty Generics Total			689.8
Segment net sales			2,749.4
Medicaid lawsuit			(536.0)
Net sales			$	2,213.4

3